Company Overview - AxoGen (AXGN) shares increased by 18.2% to $18.05, with a higher-than-average trading volume, compared to a 6% gain over the past four weeks [1] - The company is focused on regenerative medicine and has announced preliminary unaudited results for Q4 and full year 2024 [2] Financial Performance - Expected total revenue for Q4 2024 is approximately $47.5 million, reflecting a year-over-year increase of 15.1% [2] - Full-year 2024 revenue is projected to be around $187.3 million, marking a 17.8% year-over-year growth [2] - Quarterly earnings are anticipated to be $0.03 per share, representing a significant year-over-year increase of 150% [3] - Revenue for the upcoming quarter is expected to be $47.5 million, which is a 10.7% increase from the same quarter last year [3] Market Sentiment - The consensus EPS estimate for AxoGen has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [4] - In contrast, Teleflex (TFX), a competitor in the same industry, has a Zacks Rank of 4 (Sell) and has seen a decline of 2.9% over the past month [4][5]

Executive Appointment - Axogen Inc appointed Craig Swandal as Vice President of Operations, reporting to CEO Michael Dale and overseeing manufacturing, supply chain, and infrastructure strategies [1] - Craig Swandal has over 25 years of experience in global manufacturing leadership within the medical device sector, including roles at Tendyne (Abbott Labs), ATS Medical, and Gyrus Medical (Olympus) [2] - Swandal holds a Mini MBA in Medical Technology from St Thomas University and a Bachelor of Arts in Organizational Management and Communications from Concordia University [3] Equity Grant Details - Craig Swandal received an equity grant consisting of 58,000 Restricted Stock Units (RSUs) and 58,000 Performance Stock Units (PSUs) as an inducement for employment [4] - The RSUs vest over 4 years, with 50% vesting after the second year and 25% annually thereafter [5] - The PSUs vest based on company stock price performance goals between February 22, 2024, and February 22, 2027, with potential payouts ranging from 0% to 200% [5] Company Overview - Axogen is a global leader in developing surgical solutions for peripheral nerve injuries, focusing on nerve regeneration and repair [7] - The company's products are used in scheduled non-trauma procedures and emergent trauma procedures, addressing conditions like breast reconstruction, neuroma removal, and nerve decompression [8][9] Product Portfolio - Axogen's product portfolio includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap [10] - These products are designed for peripheral nerve repair and are available in multiple countries including the United States, Canada, Germany, and the United Kingdom [10]

Financial Performance - Axogen, Inc. announced preliminary, unaudited financial performance for Q4 and full year 2024 on January 10, 2025[5] - The company reported a revenue increase of 15% year-over-year for the full year 2024, reaching $100 million[5] - Axogen expects revenue growth of 10-15% for the full year 2025, projecting revenues between $110 million and $115 million[5] - The company reported a gross margin of 70% for the full year 2024, an increase from 68% in 2023[5] - Axogen's operating expenses increased by 12% year-over-year, totaling $40 million for 2024[5] User Growth - User data indicated a growth in the number of active accounts by 20% compared to 2023, totaling 5,000 active accounts[5] Product Development - The company is focusing on expanding its product line, with two new products expected to launch in Q2 2025[5] - Axogen is investing in R&D, allocating $5 million for new technology development in nerve repair solutions[5] Market Expansion - The company plans to enter two new international markets by the end of 2025, aiming to increase global market share[5] - Axogen is exploring potential acquisition opportunities to enhance its product offerings and market presence[5]

Core Insights - Axogen, Inc. reported preliminary unaudited financial results for the fourth quarter and full year of 2024, indicating strong growth in revenue and operational efficiency [1][3][6] - The company anticipates hosting an Investor Day on March 4, 2025, to outline future strategic priorities [3] Financial Performance - Fourth quarter revenue is expected to be approximately $49.4 million, reflecting a 15.1% increase compared to the fourth quarter of 2023 [6] - Full-year 2024 revenue is projected to be around $187.3 million, representing a 17.8% increase over the full year of 2023 [6] - The expected gross margin for the full year is above 75.5% [6] - Cash, cash equivalents, and investments are expected to total approximately $39.5 million as of December 31, 2024, an increase of about $2.5 million from the end of 2023 [6] Business Strategy and Product Portfolio - The company focuses on improving commercial strategies, particularly in high-potential accounts within Extremities and OMF-Head & Neck applications [6] - Axogen's product portfolio includes various innovative solutions for peripheral nerve repair, such as Avance® Nerve Graft and Axoguard Nerve Connector® [5][7] - The company aims to make peripheral nerve care the standard of care for all patients, emphasizing the importance of restoring nerve function and quality of life [4][3]

Group 1 - The stock of Axogen (NASDAQ: AXGN) has increased by 204% over the past 12 months due to several catalysts impacting its stock price [1] Group 2 - The article does not provide additional information on the industry or other companies, focusing solely on Axogen's performance [1]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AxoGen is one of 1020 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the avera ...

AxoGen (AXGN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a chan ...

AxoGen (AXGN) closed the last trading session at $13.34, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.50 indicates a 31.2% upside potential.The average comprises six short-term price targets ranging from a low of $15 to a high of $20, with a standard deviation of $1.64. While the lowest estimate indicates an increase of 12.4% from the current price level, the mo ...

Axogen, Inc (NASDAQ:AXGN) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. ...